CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland.  Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com.

Happy Thanksgiving from all of us at CNS Pharmaceuticals! We hope you enjoy a day of good company and good food.

Florida Girl, 8, Girl, Spends Holiday In DC For Rare Brain Cancer Treatment  https://ibn.fm/7js7F

Industry News:    Brain Cancer Thrives By Hijacking Mechanisms To Boost Synapse Strength  https://ibn.fm/dTSps     #braincancer  #glioblastoma #neuro-oncology

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

https://bit.ly/3MW5gmv 
#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:   Finger-prick Test Could Help Spot Brain Cancer Recurrence Sooner  https://ibn.fm/H3BYY    #braincancer  #glioblastoma #neuro-oncology

Meet our dedicated, experienced team here: https://bit.ly/3tCAjx9 

#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:    Actor Had Brain Tumor The Size Of A Lime  https://ibn.fm/gEjkC    #braincancer  #glioblastoma #neuro-oncology

Watch this video on how our lead product candidate, Berubicin is designed to work: https://bit.ly/3ZWWubF  

#GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

https://bit.ly/46fHoB9 
 #GlioblastomaMultiforme #GBM #Oncology #Glioblastoma

Industry News:   Lung Cancer Cells Covertly Thrive In Brain Under Guise Of Protection, Stanford Medicine Study Finds  https://ibn.fm/zAqz9   #braincancer  #glioblastoma #neuro-oncology

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue
gross profit
selling and marketing expenses
general and administrative expenses	860.52K -	1.98M 129.94%	4.39M 122.01%	4.68M 6.56%	5.97M 27.48%	4.77M 20.07%
selling general and administrative expenses	860.52K -	1.98M 129.94%	4.39M 122.01%	4.68M 6.56%	5.97M 27.48%	4.77M 20.07%
research and development expenses	21.27K -	1.85M 8,619.30%	5.06M 172.97%	9.35M 84.65%	9.30M 0.50%	14.10M 51.56%
other expenses	-6.46M -
cost and expenses	881.79K -	3.83M 334.68%	9.45M 146.66%	14.03M 48.36%	15.27M 8.84%	18.87M 23.57%
operating expenses	881.79K -	3.83M 334.68%	9.45M 146.66%	14.03M 48.36%	15.27M 8.84%	18.87M 23.57%
interest expense	46.70K -	44.23K 5.27%	3.26K 92.62%	9.29K 184.47%	7.03K 24.32%	-13.80K 296.46%
ebitda	-7.35M -	-3.83M 47.82%	-9.44M 146.38%	-14.01M 48.40%	-15.26M 8.86%	-18.87M 23.66%
operating income	-881.79K -	-3.83M 334.68%	-9.45M 146.66%	-14.03M 48.36%	-15.27M 8.84%	-18.87M 23.57%
depreciation and amortization	-6.46M -	1.96K 100.03%	11.10K 467.57%	13.07K 17.79%	11.76K 10.05%
total other income expenses net	-6.46M -	-44.23K 99.32%	-3.26K 92.62%	-9.29K 184.47%	-7.03K 24.32%	13.88K 297.55%
income before tax	-7.39M -	-3.88M 47.55%	-9.46M 143.93%	-14.04M 48.41%	-15.27M 8.82%	-18.85M 23.42%
income tax expense	46.70K -	42.28K 9.46%	3.26K 92.28%	9.29K 184.47%	7.03K 24.32%
net income	-7.39M -	-3.92M 46.98%	-9.46M 141.39%	-14.05M 48.46%	-15.28M 8.79%	-18.85M 23.36%
weighted average shs out	439.11K -	454.93K 3.60%	553.95K 21.77%	878.44K 58.58%	1.36M 55.02%	3.77M 176.66%
weighted average shs out dil	439.11K -	454.93K 3.60%	553.95K 21.77%	878.44K 58.58%	1.36M 55.02%	3.77M 176.66%
eps	-16.83 -	-8.62 48.78%	-17.08 98.14%	-15.99 6.38%	-11.22 29.83%	-5 55.44%
epsdiluted	-16.83 -	-8.62 48.78%	-17.08 98.14%	-15.99 6.38%	-11.22 29.83%	-5 55.44%

COM:CNSPHARMA

CNS Pharmaceuticals, Inc.

Last Close

0.13

22/11 21:00

Market Cap

1.52M

Beta: -

Volume Today

194.47K

Avg: -

Preview